Abstract
Objective:To investigate the effect of neoadjuvant chemotherapy combined with surgery on locally advanced breast cancer and its prognosis.Methods:One hundred and fifty-four patients with locally advanced breast cancer who were admitted to our hospital from February 2014 to April 2015 were selected as the study subjects. They were divided into an observation group and a control group according to the principle of random equalization, 77 each group. The observation group was treated with TAC scheme, neoadjuvant chemotherapy combined with modified radical resection, and continuously treated with the same scheme after operation until the end of the course of treatment. The control group was treated with modified radical resection and TAC scheme. The clinical efficacy of the two groups was observed, and the perioperative indications, prognosis and occurrence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 76.62%, significantly higher than that of the control group (55.84%, P<0.05). The observation group had shorter operation time and hospitalization time and less bleeding amount compared to the control group (P<0.05). The metastasis rate and recurrence rate of the observation group were significantly lower than those of the control group (P<0.05); there was a significant difference between the two groups (P<0.05). The one-year and three-year survival rates of the observation group were significantly higher than those of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups after operation (P>0.05).Conclusion:Preoperative neoadjuvant chemotherapy in combination with TAC scheme can reduce the difficulty of operation, improve the curative effect of patients, significantly improve the prognosis of patients and prolong the survival time, which is worth clinical application.
Highlights
Breast cancer, a clinically common female malignant tumor with an increasing incidence in recent years, has ranked the first among all female malignant tumors.[1,2] Currently, it is widely believed that breast cancer is a systemic disease that is highly prone to metastasis.[3,4] Locally advanced breast cancer (LABC) mainly refers to breast cancer with diameter of primary tumor lesions more than 5 cm (T3), skin and chest wallPak J Med Sci September - October 2019 Vol 35 No 5 www.pjms.org.pk 1402 adhesion (T4) or regional lymph node fusion (N2).[5]
This study explored the application and safety of TAC neoadjuvant chemotherapy combined with surgery in the treatment of LABC to provide a reference for the rational selection of neoadjuvant chemotherapy
A total of 154 patients with LABC who were admitted to our hospital from February 2014 to April 2015 were randomly divided into an observation group and a control group, 77 each
Summary
A clinically common female malignant tumor with an increasing incidence in recent years, has ranked the first among all female malignant tumors.[1,2] Currently, it is widely believed that breast cancer is a systemic disease that is highly prone to metastasis.[3,4] Locally advanced breast cancer (LABC) mainly refers to breast cancer with diameter of primary tumor lesions more than 5 cm (T3), skin and chest wallPak J Med Sci September - October 2019 Vol 35 No 5 www.pjms.org.pk 1402 adhesion (T4) or regional lymph node fusion (N2).[5]. Postoperative tumors tend to remain on the chest wall and skin edge, which leads to a high recurrence rate.[8] In recent years, the treatment of LABC has made great progress with the development of neoadjuvant chemotherapy, and a study showed that the use of neoadjuvant chemotherapy before surgery could effectively reduce tumor lesions.[9] Neoadjuvant chemotherapy can degrade the clinical stages for patients, improve the surgical resection rate, facilitate the clarification of the sensitivity of chemotherapy drugs to treat tumors, and control the potential micrometastasis to prevent distant metastasis.[10,11] the current selection of therapeutic schemes and treatment cycle for neoadjuvant chemotherapy remain controversial.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
